Cipla Introduces Afrezza - Ultra-Rapid Acting Inhaled Insulin for Adults with Diabetes in India Dr. Bhumika Maikhuri16 March 2026 11:45 AM ISTCipla Limited has announced the launch of Afrezza, the world's only available inhaled insulin for adults living with Diabetes Mellitus, offering a...
Inhaled Technosphere Insulin use tied to Modest HbA1c Increase in Youth With Diabetes at end of one year: Study Jacinthlyn Sylvia13 March 2026 10:00 AM ISTA new study published in the journal of Diabetes Technology & Therapeutics showed that the use of inhaled technosphere insulin was linked to a...
Cipla Launches Afrezza in India: Revolutionizing Diabetes Care with Needle-Free Inhaled Insulin Dr. Bhumika Maikhuri11 March 2026 10:45 AM ISTWith many diabetes mellitus (DM) patients struggling with the challenges of multiple daily insulin injections, there is a growing need for ...
Use of Inhaled Insulin not associated with increased risk of lung cancer, reports research Dr Riya Dave10 Feb 2026 12:00 PM ISTResearchers have found in a new study that inhaled insulin showed no increased risk of lung cancer compared with regular human insulin (RAA). However,...
FDA Accepts sBLA for inhaled insulin for kids and adolescents Following Positive Phase 3 Results Dr. Kamal Kant Kohli15 Oct 2025 9:15 AM ISTThe FDA has accepted MannKind's supplemental biologics license application (sBLA) for Afrezza (insulin human inhalation powder) to treat children and...
Inhaled Insulin Shows Promise as Safe Option for diabetes management in Pregnancy: Study Dr. Shravani Dali24 Aug 2025 10:30 PM ISTA study published in Pregnancy suggests that inhaled technosphere insulin may be a safe alternative to rapid-acting insulin analogs for diabetes...
Inhaled Insulin Shows Promise in Enhancing Type 1 Diabetes Management: INHALE-3 Trial Medha Baranwal24 Jun 2024 6:00 PM ISTUSA: Results from INHALE-3, a clinical trial investigating inhaled insulin in adults with type 1 diabetes, demonstrated its safety and efficacy in...
